808 results about "Biguanide" patented technology

A dermatological composition comprising a salt of a cation and an anion. The cation is derived from a monomeric or polymeric molecule that will generate an amidine moieity, a guanidine moieity or a biguanide moieity. The anion is derived from a monomeric or polymeric molecule that will generate a carboxylic acid moieity. The composition may be prepared by a metathesis or acid-base reaction.

This invention is directed to a novel method and composition for the treatment of diabetes mellitus (Type I, Impaired Glucose Tolerance ["IGT"]and Type II). More specifically, this invention pertains to a novel method of treating diabetes mellitus by incorporating a therapeutic amount of one or more insulin sensitizers along with one or more of an orally ingested insulin, an injected insulin, a sulfonylurea, a biguanide or an alpha-glucosidase inhibitor for the treatment of diabetes mellitus.

Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including a cationic antiseptic such as biguanides and bisbiguanides such as chlorhexidine and its various salts including but not limited to the digluconate, diacetate, dimethosulfate, and dilactate salts; polymeric quaternary ammonium compounds such as polyhexamethylenebiguanide; silver and various silver complexes; small molecule quaternary ammonium compounds such as benzalkoium chloride and alkyl substituted derivatives; di-long chain alkyl (C8-C18) quaternary ammonium compounds; cetylpyridinium halides and their derivatives; benzethonium chloride and its alkyl substituted derivatives; and octenidine. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and / or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and / or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).

A highly safe and effective prophylactic / ameliorating or therapeutic agent for NACH and the method for using the same are provided.A prophylactic / ameliorating or therapeutic agent for NASH containing a combination of at least one first ingredient selected from the group consisting of an ω3PUFA and pharmaceutically acceptable salts and esters thereof and at least one second ingredient selected from the group consisting of (a) a biguanide hypoglycemic agent, (b) a nonsteroidal anti-inflammatory drug, (c) a 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor, and (d) an angiotensin II receptor blocker as the active ingredients; and its method of use.

An antimicrobial composition that involves a synergistic mixture in terms of active agents, of a primary antimicrobial agent, such as polyhexamethylene biguanide (PHMB), a secondary antimicrobial agent, and optionally an organic acid against various kinds of microbes is described. Various additional processing aids, such as alcohols and surfactants, may also be incorporated within the mixture. The composition allows one to use a significantly less concentration of individual constituent antimicrobial agents to achieve the same or a better degree of antimicrobial efficacy. The antimicrobial composition can be applied to the surface of almost any kind of substrate material, and can achieve a killing-efficacy of about 3 Log10 reduction in microbes within 30 minutes under ambient conditions.

The present invention provides pharmaceutical agents comprising a dipeptidyl peptidase IV (DPPIV) inhibitor and a biguanide agent in combination, which enhance the effects of active circulating glucagon-like peptide-1 (GLP-1) and / or active circulating glucagon-like peptide-2 (GLP-2).

The invention describes formulations that include either metformin, sulfonylurea or a biguanide-sulfonylurea combination as one active ingredient in addition to specific, other active ingredients. The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of the included biguanide (metformin) and / or sulfonylurea in the prevention and treatment of insulin resistance and diabetes mellitus. The carefully chosen additional active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and those adverse incidences associated with the concurrent use of metformin and / or the sulfonylureas. When clinically administered, the invention will provide therapeutic levels of metformin and of a sulfonylurea, alone or in combination, and broaden their usefulness. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.

A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.

This invention a pharmaceutical composition comprising a DPP inhibitor and a slow release biguanide. The invention further discloses a method of administering a combination comprising a DPP inhibitor and a slow release biguanide to a mammal in need of thereof.

This invention is directed to a pharmaceutical composition in the form of a tablet with improved stability, as well as the process for obtaining said composition. The tablet of the present invention comprises two active ingredients comprising two oral hypoglycemic agents: one phase with a sulphonylurea, such as immediate release Glimepiride, and a second phase with a biguanide, such as extended-release Metformin hydrochloride (Metformin HCl). The biphasic tablet, which can include over 500 mg of Metformin HCl (i.e. up to 1,000 or 1,500 mg, depending on the daily requirements of each patient), is to be orally administered once or twice a day. The combination of these hypoglycemic agents has a synergic effect and therefore a greater effectiveness in controlling the blood glucose level in patients with diabetes mellitus, type 2.

A cleaning and biocidal composition in liquid form comprising a solvent, a polymeric biguanide, a single quaternary ammonium salt, a sequestrant, and at least one surfactant. The composition comprising the solvent including water, the polymeric biguanide including a polyhexamethylene biguanide hydrochloride, the quaternary ammonium salt including a didecyldimethyl ammonium chloride, the sequestrant including an amino acid chelating agent selected from the group consisting of: ethylenediaminetetraacetic acid, nitrilotriacetic acid, tetrasodium ethylenediaminetetraacetic acid, or mixtures thereof, the surfactant including a non-ionic surfactant and an amphoteric surfactant.

This invention provides a pharmaceutical agent containing, in combination, a sulfonamide compound and other therapeutic agent, preferably, at least one compound represented by the formula (I): R1—SO2—NH—CO-A1-CH2—R2 [each symbol is as defined in the specification] or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical agent selected from the group consisting of an α-glucosidase inhibitor, an insulin secretagogue, a sulfonylurea and a biguanide, which has a superior therapeutic effect.

Insulin sensitivity increasing substances (ISIS), including but not limited to D-chiro-inositol, thiazolidinedione and derivatives, and biguanides, are useful in the treatment of hair loss and other disorders of the pilosebaceous apparatus (hirsutism, acne, etc.) associated with conditions of excess insulin and / or insulin resistance. The treatment comprises administering to a mammal, such as a human, at least one ISIS either alone or in combination with at least one agent, such as an androgen receptor blocker (ARB) and / or a steroid enzyme inhibitor or inducer (STI). Additionally, an activity enhancing agent may be included for topical administration.

A synergistic antimicrobial composition containing at least two kinds of antimicrobial agents, including poly-hexamethylene biguanide (PHMB), stably associated to a material substrate is described. The substrate can take the forms of an anti-infection face mask, medical devices, or surgical instruments.

An antimicrobial composition with synergistic biocidal activity is described which comprises at least one antimicrobial polymeric biguanide and at least one antimicrobial vicinal diol, said vicinal diol comprises at least one monoalkyl glycol, monoalkyl glycerol, or monoacyl glycerol, to diminish or eliminate biofilm communities. Such synergistic interaction is effective in wound treatment, particularly for chronic wounds, burns and battlefield-induced wounds, as well as for disinfecting non-biological surfaces. The antimicrobial composition can also be prepared as viscous solutions or as gels. The antimicrobial composition may be added to a substrate and dried, such as to a catheter, or to a foam, or to a fiber wound dressing, or coated as a viscous solution or gel upon such devices, to provide controlled release antimicrobial activity.

Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

A novel patient-convenient, cost effective pharmaceutical composition, comprising of thiazolidinediones and biguanide for controlling hyperglycemia manufactured as multilayer tablet and its process of manufacturing, for immediate release of thiazolidinediones or thiazolidinediones and biguanide and prolonged release of the biguanide only, the tablet comprising of minimum two layers wherein one outer layer comprises of a mixture of excipients and thiazolidinediones or thiazolidinediones and biguanide allowing immediate release of thiazolidinediones or thiazolidinediones and biguanide respectively and the other layer arranged in contact with the immediate release layer which comprises of a novel composition of excipients and a minimum one or more non-biodegradable, inert polymer(s) and the biguanide allowing pH independent prolonged release of the biguanide up to a period of 8-12 hours. The tablets are for once a day dosing. The tablets may optionally be film coated or enrobed by soft gelatin ribbons for additional protection against oxidation, photodegradation, identification, ease of swallowing, taste masking and for aesthetic appeal without altering the dissolution profile.

An improved cleaning composition adapted to clean a variety of hard surfaces. The improved cleaning composition includes a cationic biocide that includes biguanide compounds and / or quats.

The present invention provides antimicrobial solutions that in certain cases comprise a biguanide and a glycol ether and, in some cases, optionally also includes combinations of at least one an alcohol, at least one chelator, glycerol, deoxycholate, and / or at least one alkylpolyglucoside. In certain aspects the invention comprises a biguanide and deoxycholate or a combination of chelator, ethanol, and alkylpolyglucoside. Also provided are methods for rapidly killing and / or reducing bacteria, fungi, or virus from surfaces, for example, including surfaces of indwelling medical devices and organic surfaces such as skin and sutures, and inorganic surfaces such as medical equipment, pipelines etc.

Antimicrobial lubricant compositions are disclosed. The antimicrobial lubricant compositions are particularly useful in providing antimicrobial capability to a wide-range of medical devices. The compositions include an oil lubricant. Representative lubricants may include polydimethyl siloxane, trifluoropropyl copolymer polysiloxane, and a copolymer of dimethylsiloxane and trifluoropropylmethylsiloxane. The compositions include rheology modifiers as necessary. The compositions also include antimicrobial agents, which may be selected from a wide array of agents. Representative antimicrobial agents include of aldehydes, anilides, biguanides, bis-phenols, quaternary ammonium compounds, cetyl pyridium chloride, cetrimide, alexidine, chlorhexidine diacetate, benzalkonium chloride, and o-phthalaldehyde.

An improved cleaning composition adapted to clean a variety of hard surfaces. The improved cleaning composition includes a cationic biocide that includes biguanide compounds and / or quats.

This invention is directed to a novel method and composition for the treatment of diabetes mellitus (Type I, Impaired Glucose Tolerance ["IGT"] and Type II). More specifically, this invention pertains to a novel method of treating diabetes mellitus by incorporating a therapeutic amount of one or more insulin sensitizers along with one or more of an orally ingested insulin, an injected insulin, a sulfonylurea, a biguanide or an alpha-glucosidase inhibitor for the treatment of diabetes mellitus.

The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and / or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and / or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.

Polyethyleneimine and polyalkylene biguanide ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed.

A family of infection resistant and biocidal polymeric materials incorporates an infection resistant biguanide such as chlorhexidine or polyhexanide pendant to the polymer chain, chemically linked to the polymer through the biguanide group secondary nitrogen atoms. The disclosure extends to the use of such polymeric materials in articles of manufacture and particularly in medical devices, and the preparation of the materials as polymer resins from which articles can be made, as solutions and emulsions which can be used for coating performed articles, and in situ on the surface of preformed polymeric articles.

The present invention relates to a composition comprising: (i) an anti-microbial agent comprising a polymeric biguanide, alone or in combination with at least one other microbiologically active component selected from the group consisting of quaternary ammonium compounds, monoquaternary heterocyclic amine salts, urea derivatives, amino compounds, imidazole derivatives, nitrile compounds, tin compounds or complexes, isothiazolin-3-ones, thiazole derivatives, nitro compounds, iodine compounds, aldehyde release agents, thiones, triazine derivatives, oxazolidine and derivatives thereof, furan and derivatives thereof, carboxylic acids and the salts and esters thereof, phenol and derivatives thereof, sulphone derivatives, imides, thioamides, 2-mercapto-pyridine-N-oxide, azole fungicides, strobilurins, amides, carbamates, pyridine derivatives, compounds with active halogen groups, and organometallic compounds; and (ii) an amphoteric co-polymer of the Formula (1): wherein:[A] is of Formula (9), [B] is of Formula (10), [C] is of Formula (12), [D] is of Formula (13), and X is of Formula (11), wherein [A], [B], [C] and [D] may occur in any order; T is an optionally substituted substituent; L, G and Z each independently is an optionally substituted linking group; R1, R2 and R3 are each independently H, optionally substituted C1-20-alkyl or optionally substituted C3-20-cycloalkyl; R4 and R5 are each independently H or C1-4-alkyl; q is 15 to 1000; p is 3 to 50; J is an optionally substituted hydrocarbyl group; F is an acidic substituent; E is a basic substituent; m is 0 to 350; n is 1 to 75; v is 0 to 100; y is 1 to 100; b is 0, 1 or 2; s is 0 or 1; w is 1 to 4; and provided that at least one of R4 and R5 is H.

An improved cleaning composition and method adapted to clean a variety of hard surfaces. The improved cleaning composition and method includes the use of a cationic biocide that includes biguanide compounds and / or quats.

The invention discloses a chemical-mechanical polishing solution. The chemical-mechanical polishing solution contains ground particles and water and also contains biguanide compound and nitrogen and azole compound, wherein the biguanide compound and the nitrogen and azole compound have synergistic effect and can remarkably improve the elimination rate of polysilicon.